Bayer’s Nexavar appeal rejected by Indian Supreme Court

16-12-2014

Bayer’s Nexavar appeal rejected by Indian Supreme Court

360b / Shutterstock.com

Bayer has lost an attempt to block a generic version of its cancer drug Nexavar (Sorafenib) in India after the country’s highest court rejected an appeal from the German pharmaceutical company.


Bayer, Nexavar, Supreme Court of India, Natco Pharma, compulsory licence

LSIPR